Abstract
Background:
The coronavirus disease 2019 (COVID-19) pandemic, made worse by the JN 2 variant, required immediate and effective treatments, particularly for serious breathing issues and after effects from the infection, such as lung scarring.

Aim:
This study aimed to examine the safety of nebulized frozen human platelet-rich plasma (PRP) in guinea pigs, an important model for understanding practical uses. The main goal of this study is to assess the safety and effectiveness of nebulized lyophilized human PRP in guinea pigs, particularly considering its potential use in larger mammalian models and humans.

Methods:
The experimental design involves subjecting guinea pigs to a 25-day exposure to lyophilized PRP, followed by a 15-day recovery period. PRP is administered through nebulization. Morbidity, mortality, clinical parameters, organ weights, and histopathological findings were assessed.

Results:
The results of the study demonstrate promising outcomes, with no observed morbidity or mortality in the guinea pig test groups. Moreover, no significant alterations in clinical parameters, organ weights, or histopathological findings were observed following the 25-day exposure and 15-day recovery period.

Conclusion:
This groundbreaking transspecies study introduces human blood PRP in guinea pigs, emphasizing its safety and efficacy when administered via a nebulizer. By extending the investigation to guinea pigs, we aim to bridge the gap between preclinical studies and potential human applications. Nebulized PRP maintains molecular levels and bioactivity, demonstrating its potential as a targeted therapy for lung-related complications. The study calls for further exploration of nebulized PRP in clinical trials, especially for treating COVID-19 and respiratory infections, particularly in the context of pulmonary fibrosis. This study holds promise for enhancing the overall quality of life of individuals with severe respiratory conditions. The ease of administration is also an important attribute that ensures patient compliance.

Key words: Nebulized platelet-rich plasma; Pulmonary fibrosis; COVID-19; Guinea pig model; Respiratory therapy.